admin | September 6, 2023

The novel BCR::ABL1 allosteric inhibitor TERN-701 is potent against mutations resistant to active site tyrosine kinase inhibitors (TKIs) and acts synergistically with TKIs in BCR::ABL1+ cancer cell lines

The novel BCR::ABL1 allosteric inhibitor TERN-701 is potent against mutations resistant to active site tyrosine kinase inhibitors (TKIs) and acts synergistically with TKIs in BCR::ABL1+ cancer cell lines